Evolution of Drug Development: Integrating the Patient Perspective Into Early Research

被引:0
|
作者
Yanni, Anthony J. [1 ]
Fine, Jennifer [2 ]
机构
[1] Sanofi R&D, Med Intelligence & Patient Perspect, 55 Corp Dr, Bridgewater, NJ 08807 USA
[2] Sanofi R&D, Med Intelligence & Patient Perspect, Chilly Mazarin, France
关键词
patient perspective; unmet need; medical value; risk/opportunity assessment; medical intelligence;
D O I
10.1177/2168479017716492
中图分类号
R-058 [];
学科分类号
摘要
Soaring drug development costs, increasingly stringent regulatory requirements, and demanding market access environments have necessitated that pharmaceutical companies examine their research processes in order to provide novel and meaningful solutions for patients. In this paper, we describe an initiative that aims to incorporate a better appreciation of the exam room experience of both patients and practitioners into the drug development pathway from the earliest point of research. Focusing on 4 core pillarsmedical value, patient need, scientific rationale, and market environmentan integrated analytic process is undertaken so as to facilitate early identification of ideal target populations and criteria that will need to be met for successful entry into the treatment continuum. Collaborative interactions with other specialist roles within the organization are also described. It is argued that understanding the unmet medical need and the risks and opportunities inherent in different development scenarios can help direct early research so as to encourage truly transformative health care solutions.
引用
收藏
页码:89 / 93
页数:5
相关论文
共 50 条
  • [1] Evolution of Drug Development: Integrating the Patient Perspective Into Early Research
    Anthony J. Yanni
    Jennifer Fine
    Therapeutic Innovation & Regulatory Science, 2018, 52 : 89 - 93
  • [2] INTEGRATING THE PATIENT PERSPECTIVE IN FORMULATION RESEARCH
    Lech, Laura Victoria Jedig
    Bjornsdottir, Ingunn
    Almarsdottir, Anna Birna
    Norgaard, Lotte Stig
    Jacobsen, Ramune
    Tiihonen, Miia
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2019, 15 (12): : E53 - E54
  • [3] REENGINEERING DRUG DEVELOPMENT - INTEGRATING PHARMACOECONOMIC RESEARCH INTO THE DRUG DEVELOPMENT PROCESS
    DATA, JL
    WILLKE, RJ
    BARNES, JR
    DIROMA, PJ
    PSYCHOPHARMACOLOGY BULLETIN, 1995, 31 (01) : 67 - 73
  • [4] Evolution of a research team: the patient partner perspective
    Madison S.
    Colon-Moya A.D.
    Morales-Cosme W.
    Lorenzi M.
    Diaz A.
    Hickson B.
    Monteiro K.
    Muniz Ruiz A.
    Perez A.
    Redondo R.
    Reid D.
    Robles J.
    Santiago M.
    Thompson O.
    Wade J.
    White M.
    Castillo G.
    Valenzuela C.
    Research Involvement and Engagement, 8 (1)
  • [5] On target? The challenge of integrating biomarker research in drug development
    Carney, Walter
    BIOMARKERS IN MEDICINE, 2007, 1 (01) : 17 - 21
  • [6] Reflections on the Evolution of Patient Engagement in Drug Development
    Kenneth Getz
    Pharmaceutical Medicine, 2019, 33 : 179 - 185
  • [7] Reflections on the Evolution of Patient Engagement in Drug Development
    Getz, Kenneth
    PHARMACEUTICAL MEDICINE, 2019, 33 (03) : 179 - 185
  • [8] EVOLUTION OF A RESEARCH TEAM: THE PATIENT-PARTNER PERSPECTIVE
    Colon, Alex
    Madison, Suzanne M.
    Cosme, Wilfredo Morales
    Lorenzi, Margie
    Diaz, Aracelis
    Hickson, Bridget
    Monteiro, Kathy
    Muniz, Alexander
    Perez, Addie
    Redondo, Richard A.
    Reid, Dennis
    Robles, Janet
    Santiago, Marsha
    Thompson, Opal
    Wade, Joyce
    White, Mary
    Castillo, Graciela
    Valenzuela, Cristian
    CHEST, 2022, 162 (04) : 1487A - 1488A
  • [9] A Perspective on the Prediction of Drug Pharmacokinetics and Disposition in Drug Research and Development
    Di, Li
    Feng, Bo
    Goosen, Theunis C.
    Lai, Yurong
    Steyn, Stefanus J.
    Varma, Manthena V.
    Obach, R. Scott
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (12) : 1975 - 1993
  • [10] Integrating artificial intelligence in drug discovery and early drug development: a transformative approach
    Alberto Ocana
    Atanasio Pandiella
    Cristian Privat
    Iván Bravo
    Miguel Luengo-Oroz
    Eitan Amir
    Balazs Gyorffy
    Biomarker Research, 13 (1)